← Back to home

RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (INCLUDING SMALL LYMPHOCYTIC LYMPHOMA)

Clinical trials for RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (INCLUDING SMALL LYMPHOCYTIC LYMPHOMA) explained in plain language.

Never miss a new study

Get alerted when new RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (INCLUDING SMALL LYMPHOCYTIC LYMPHOMA) trials appear

Sign up with your email to follow new studies for RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (INCLUDING SMALL LYMPHOCYTIC LYMPHOMA), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

Drug safety under the microscope for Tough-to-Treat blood cancer

Disease control Completed

This study monitored the safety of the drug Calquence (acalabrutinib) in a real-world setting after it was approved for use. It involved 104 patients whose chronic lymphocytic leukemia had returned or did not respond to prior treatment. The main goal was to track the frequency an…

Matched conditions: RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (INCLUDING SMALL LYMPHOCYTIC LYMPHOMA)

Sponsor: AstraZeneca • Aim: Disease control

Last updated Mar 23, 2026 15:17 UTC

RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (INCLUDING SMALL LYMPHOCYTIC LYMPHOMA)

Get alerted when new RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (INCLUDING SMALL LYMPHOCYTIC LYMPHOMA) trials appear

Drug safety under the microscope for Tough-to-Treat blood cancer